Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is a biopharmaceutical company that currently has three products in the market with potential for significant upside potential from its royalty and collaboration revenue streams. The company has a strong balance sheet, with a cash balance of $134M after settling its remaining senior convertible notes. MannKind's potential for success in the pediatric market with its insulin product, Afrezza, could be a major driver for revenue growth in the future. The company also has multiple other significant catalysts in 2026, including a potential label expansion for its product used to treat fluid buildup in heart failure patients, that could lead to a compelling risk-reward scenario for investors.

Bears say

MannKind is facing numerous challenges including commercial execution risks, clinical trial risks, and regulatory risks, which could hinder the success of its flagship products Afrezza, Furoscix, and V-Go. Additionally, the pending FDA decision on the ReadyFlow autoinjector for Furoscix could bring significant growth potential, but success is not guaranteed and delays or rejections could have a negative impact on the stock price. Furthermore, the company's valuation and price target are based on a discounted cash flow model with a 10.2% WACC and a 13.0x exit multiple on 2031 estimates, which reflects the inherent risk and uncertainty in the company's future performance.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.